Serum levels of sgp130 were higher in MS patients, homozygote of the protective allele of MS risk SNPs, reaching significance for rs7731626 (Figure 8D), and this is concordant with a recent publication showing significantly increased serum sgp130 levels in MS carriers of the protective allele of the correlated MS risk SNP rs71624119 (58; Figure 1). Here, IL6ST is linked to myeloid sarcoma.